Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
57 Cards in this Set
- Front
- Back
|
Iron Dextran |
used IV to treat iron deficiency can elicit anaphylactic reactions |
|
|
Deferoxamine |
Iron chelator used for iron overload |
|
|
Drugs that can reduce B12 absorption |
H2 Histamine antagonists Proton Pump Inhibitors |
|
|
rHu-EPO |
used to stimulate RBC development in some anemia's can be thrombogenic and hypertensive |
|
|
Filgrastim |
G-CSF stimulates granulocyte development in marrow mobilizes HSC's to peripheral blood |
|
|
Sarograstim |
GM-CSF shorten nuetropenia in patients undergoing cytotoxic chemotherapy |
|
|
Oprelvekin |
IL-11 receptor agonist stimulates megakaryocyte development to treat thrombocytopenia |
|
|
Treatment for Tumor lysis syndrome |
allopurinol rasburicase |
|
|
Imatinib |
TKI used for BCR-ABL CML/ALL |
|
|
Asparaginase/Pegaspargase |
inhibits asparagine synthesis used for ALL pegylated form has longer half-life pancreatitis/blood sugar issues, and hypersensitivty |
|
|
Corticosteroids |
can be used for lymphoid cancers activates mitochondrial apoptotic pathway |
|
|
CNS Prophylaxis |
can use methotrexate intrathecally to protect against CNS infiltration by ALL |
|
|
Ibrutinib |
BTK inhibitor, orally active CLL CYP interactions, and can cause atrial fibrillation |
|
|
Idelalisib |
selective PI3K-delta inhibitor, limits proliferation signalling
hepatotoxicity, intestinal perforation, pneumonitis |
|
|
Rituximab, tositumumab, obinutuzumab, ofatumumab |
Anti-CD20+ mab's infusion reaction and immunosuppression HBV reaction, requires screening |
|
|
Venetoclax |
used for the del(17p) genotype promotes Bcl-2 degradation > cellular apoptosis |
|
|
APML treatments |
ATRA: binds receptor and promotes differentiation, orally active retinoic acid syndrome: cytokine release, fever, respiratory distress, capillary reaction, dexamethasone Arsenic trixodie: binds the K160 receptor and ubiquitinates protein, IV infusion AV block, QT prolongation |
|
|
Omecetaxine |
protein synthesis inhibitor CML independent of BCR-ABL pathway, can use in cases that have become resistant to TKI's |
|
|
Lenalidomide |
immunomodulator, anti-angiogenic, anti-tumor used for multiple myeloma and MDS peripheral sensory neuropathy, teratogen |
|
|
Ixazomib |
bortezomib, proteasomal inhibitor this one is orally active |
|
|
Daratumumab |
anti-CD38+, highly expressed in MM cells infusion reaction and immunosuppression |
|
|
Elotuzumab |
anti-SLAMF7, myeloma and NK cell surface marker NK cells have EAT2, drug stimulates activity MM cells don't have EAT2, kills cells |
|
|
Paniobinostat |
HDAC inhibitors diarrhea and cardiac toxicity |
|
|
Azacitidine |
inhibits DNA methyltransferases, cytidine analog prevent over-methylation MDS |
|
|
Alemtuzumab |
anti-CD52 CLL/SLL |
|
|
Aspirin |
selectively inhibits COX-1 in platelets GI toxicity, bronchospasm |
|
|
Clopidogrel |
blocks the P2Y-1/12 platelet ADP receptor less effective in Poor 2C9 metabolizers |
|
|
Ticlopidine |
blocks platelet ADP receptor second line therapy due to hepatotoxicity |
|
|
Dipyramidamole/Cilostazol |
phosphodiesterase inhibitors, blocks arachidonic acid release (TXA2) oral drugs |
|
|
Abiciximab |
mab fragments that antagonize GpIIb/IIIa thrombocytopenia |
|
|
Eptifibatide/Tirofiabn |
antagonize GpIIb/IIIa, but not mab fragments |
|
|
Vorapaxar |
antagonizes PAR very long half life |
|
|
Gingko, Garlic, Ginger |
Gingko/garlic: anti-platelet Garlic: inhibits TX synthesis and aggregation |
|
|
Heparin |
salt that brings antithrombin and IIa and Xa close to each other measure PTT |
|
|
Protamine sulfate |
complexes and deactivates heparin |
|
|
Low Molecular Weight Heparin |
works the same as heparin, but more specific for Xa |
|
|
Wafarin |
antagonizes vitamin K epoxide reductase preventing the regeneration of Vitamin K blocks gamma carboxylation of 2, 7, 9, 10, C, S have to bridge with heparin skin necrosis |
|
|
Phytonadione |
synthesis vitamin K1 for warfarin reversal |
|
|
Fondaparinux |
indirect Xa inhibitor, binds antithrombin |
|
|
Apixaban/Rivaroxaban |
direct Xa inhibitors no reversal agent |
|
|
Dabigatran/Bivalirudin |
binds and inhibits free and bound thrombin |
|
|
Idarucuzimab |
IV mab fragments that reverse dabigatran activity |
|
|
Alteplase |
tissue-plasminogen activator fibrinolytic, administered to acutely resolve clots |
|
|
Aminocaproic acid |
fibrinolysis inhibitor, used for hyperfibrinolytic hemorrhage short-term cardiac toxicity |
|
|
Tranexanic acid |
synthetic amino acid inhibitor of plasminogen activation IV, oral, and topical |
|
|
Maraviroc |
selective CCR5 antagonist for HIV binding hepatotoxicity |
|
|
Enfuvitide (T-20) |
HIV entry inhibitor requires SubQ injection |
|
|
Desmopressin |
synthetic ADH that can induce vWF and VIII secretion |
|
|
Emtracitabine, Stavudine, , Didanosine |
NRTI's, requires cellular phosphorylation; halts chain elongation Lactic acidosis, steatosis, lipodystrophy |
|
|
Abacavir |
NRTI must screen for HLA-B*5701 |
|
|
Zidovudine |
fetal HIV prophylaxis bone marrow suppression |
|
|
Efavirenz, Nevirapine |
NNRTI's, oral drugs all involve CYP metabolism Efavirenz: fetal risk, neuropsych, dyslipidemia Nevirapine: most hepatoxicity |
|
|
Raltegravir, (-gravir) |
inhibit integrase addition must measure creatine kinase because they inhibit renal tubular secretion |
|
|
Protease inhibitors (-navir) |
prevent the maturation of infective viral particles some CYP interactions |
|
|
Ritonavir |
inhibits CYP, boosting other drugs concentration |
|
|
Cobicistat |
booster drug that inhibits CYP3A4 |
|
|
Post HIV exposure prophylaxis |
Tenofovir and emtricitabine, and an integrase inhibitor |
